Paris Panayiotopoulos Net Worth

The estimated Net Worth of Paris Panayiotopoulos is at least $340 Mille dollars as of 30 November 2017. Paris Panayiotopoulos owns over 3,215 units of Corbus Pharmaceuticals Inc stock worth over $340,085 and over the last 8 years Paris sold CRBP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paris Panayiotopoulos CRBP stock SEC Form 4 insiders trading

Paris has made over 2 trades of the Corbus Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Paris bought 3,215 units of CRBP stock worth $99,569 on 30 November 2017.

The largest trade Paris's ever made was buying 14,285 units of Corbus Pharmaceuticals Inc stock on 16 November 2017 worth over $100,424. On average, Paris trades about 1,750 units every 1 days since 2017. As of 30 November 2017 Paris still owns at least 6,452 units of Corbus Pharmaceuticals Inc stock.

You can see the complete history of Paris Panayiotopoulos stock trades at the bottom of the page.

What's Paris Panayiotopoulos's mailing address?

Paris's mailing address filed with the SEC is 8 SYLVAN WAY, , PARSIPPANY, NJ, 07054.

Insiders trading at Corbus Pharmaceuticals Inc

Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over $3,643,182 worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth $50,292,165 . The most active insiders traders include Asset Management, Lp Chen B..., Asset Management, Lp Cormor... e Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $1,059,576. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth $233,837.

What does Corbus Pharmaceuticals Inc do?

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.

Complete history of Paris Panayiotopoulos stock trades at Corbus Pharmaceuticals Inc

Corbus Pharmaceuticals Inc executives and stock owners

Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Yuval Cohen,
  Chief Executive Officer, Director
• Barbara White,
  Chief Medical Officer 
• Sean Moran,
  Chief Financial Officer
• Dr. Yuval Cohen,
  CEO & Director
• Rachelle Jacques,
  Independent Director
• Sean F. Moran CPA, M.B.A., CPA, MBA,
  Chief Financial Officer
• Alan Holmer,
  Independent Chairman of the Board
• Avery Catlin,
  Independent Director
• John Jenkins,
  Independent Director
• Ted Jenkins,
  Senior Director, Investor Relations and Communications
• Peter Salzmann,
  Independent Director
• Craig Millian,
  Chief Commercial Officer
• Scott Constantine,
  Sr. Director & Head of Clinical Operations
• Christina Bertsch,
  Head of HR
• Lindsey Smith,
  Head of Corp. Communications & Patient Advocacy
• Dr. Rachael Brake Ph.D.,
  Chief Scientific Officer
• Craig Stuart Millian M.B.A.,
  Chief Operating Officer.
• David P Hochman,
  Director
• Mark Tepper,
  President and CSO
• Renu Gupta,
  Director
• George Golumbeski,
  Director
• Asset Management, Lp Cormor...,
  
• Anne Altmeyer,
  
• Yong Ben,
  
• Paris Panayiotopoulos,
  Director
• Asset Management, Lp Chen B...,
  
• Dominic Smethurst,
  Chief Medical Officer
• Sumner Burstein,
  10% owner
• Robert Paul Discordia,
  Chief Operating Officer
• Rachael Louise Brake,
  Chief Scientific Officer
• Winston Kung,